BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kitazawa T, Tsujimoto T, Kawaratani H, Fukui H. Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury. J Gastroenterol Hepatol. 2009;24:1089-1094. [PMID: 19226379 DOI: 10.1111/j.1440-1746.2008.05770.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Seo M, Hong J, Kim S, Lee S. Genipin protects d -galactosamine and lipopolysaccharide-induced hepatic injury through suppression of the necroptosis-mediated inflammasome signaling. European Journal of Pharmacology 2017;812:128-37. [DOI: 10.1016/j.ejphar.2017.07.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
2 Cheng Z, Yue L, Zhao W, Yang X, Shu G. Protective effects of protostemonine on LPS/GalN-induced acute liver failure: Roles of increased hepatic expression of heme oxygenase-1. International Immunopharmacology 2015;29:798-807. [DOI: 10.1016/j.intimp.2015.08.039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
3 Gonzalez E, van Liempd S, Conde-Vancells J, Gutierrez-de Juan V, Perez-Cormenzana M, Mayo R, Berisa A, Alonso C, Marquez CA, Barr J, Lu SC, Mato JM, Falcon-Perez JM. Serum UPLC-MS/MS metabolic profiling in an experimental model for acute-liver injury reveals potential biomarkers for hepatotoxicity. Metabolomics 2012;8:997-1011. [PMID: 23139648 DOI: 10.1007/s11306-011-0329-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 4.7] [Reference Citation Analysis]
4 Wang K, Lv L, Yan R, Wang Q, Jiang H, Wu W, Li Y, Ye J, Wu J, Yang L, Bian X, Jiang X, Lu Y, Xie J, Wang Q, Shen J, Li L. Bifidobacterium longum R0175 Protects Rats against d-Galactosamine-Induced Acute Liver Failure. mSphere 2020;5:e00791-19. [PMID: 31996423 DOI: 10.1128/mSphere.00791-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Possamai LA, McPhail MJ, Khamri W, Wu B, Concas D, Harrison M, Williams R, Cox RD, Cox IJ, Anstee QM. The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. Liver Int. 2015;35:764-773. [PMID: 25244648 DOI: 10.1111/liv.12689] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
6 Zhang J, Li D, Yang W, Wang Y, Li L, Zheng H. Foot-and-Mouth Disease Virus VP3 Protein Acts as a Critical Proinflammatory Factor by Promoting Toll-Like Receptor 4-Mediated Signaling. J Virol 2021;95:e0112021. [PMID: 34524915 DOI: 10.1128/JVI.01120-21] [Reference Citation Analysis]
7 Barochia A, Solomon S, Cui X, Natanson C, Eichacker PQ. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol 2011;7:479-94. [PMID: 21323610 DOI: 10.1517/17425255.2011.558190] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 9.7] [Reference Citation Analysis]
8 Pimentel-Nunes P, Soares JB, Roncon-Albuquerque R, Dinis-Ribeiro M, Leite-Moreira AF. Toll-like receptors as therapeutic targets in gastrointestinal diseases. Expert Opin Ther Targets. 2010;14:347-368. [PMID: 20146632 DOI: 10.1517/14728221003642027] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
9 Tsujimoto T, Kawaratani H, Kitazawa T, Uemura M, Fukui H. Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis. Dig Dis Sci. 2012;57:1144-1151. [PMID: 22367065 DOI: 10.1007/s10620-012-2073-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
10 Guo J, Friedman SL. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair. 2010;3:21. [PMID: 20964825 DOI: 10.1186/1755-1536-3-21] [Cited by in Crossref: 172] [Cited by in F6Publishing: 164] [Article Influence: 14.3] [Reference Citation Analysis]
11 Liu LM, Liang DY, Ye CG, Tu WJ, Zhu T. The UII/UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-κB pathways in LPS-stimulated Kupffer cells. PLoS One 2015;10:e0121383. [PMID: 25803040 DOI: 10.1371/journal.pone.0121383] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
12 Eguchi A, Povero D, Alkhouri N, Feldstein AE. Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opin Ther Targets. 2013;17:773-779. [PMID: 23600493 DOI: 10.1517/14728222.2013.789502] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
13 Zhao C, Cui X, Zhao Y, Qian B, Zhang N, Xin L, Ha C, Yang J, Wang X, Gao X. Impact of hepatocyte-specific deletion of staphylococcal nuclease and tudor domain containing 1 (SND1) on liver insulin resistance and acute liver failure of mice. Bioengineered 2021;12:7360-75. [PMID: 34608846 DOI: 10.1080/21655979.2021.1974653] [Reference Citation Analysis]
14 Kim SJ, Lee SM. NLRP3 inflammasome activation in D-galactosamine and lipopolysaccharide-induced acute liver failure: role of heme oxygenase-1. Free Radic Biol Med 2013;65:997-1004. [PMID: 23994575 DOI: 10.1016/j.freeradbiomed.2013.08.178] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 9.9] [Reference Citation Analysis]
15 Shah N, Montes de Oca M, Jover-cobos M, Tanamoto K, Muroi M, Sugiyama K, Davies NA, Mookerjee RP, Dhar DK, Jalan R. Role of Toll-Like Receptor 4 in Mediating Multiorgan Dysfunction in Mice With Acetaminophen Induced Acute Liver Failure: Toll-Like receptor 4 in Multiorgan Dysfunction. Liver Transpl 2013;19:751-61. [DOI: 10.1002/lt.23655] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
16 Hoque R, Vodovotz Y, Mehal W. Therapeutic strategies in inflammasome mediated diseases of the liver. J Hepatol 2013;58:1047-52. [PMID: 23266490 DOI: 10.1016/j.jhep.2012.12.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
17 Schürmann M, Greiner JFW, Volland-Thurn V, Oppel F, Kaltschmidt C, Sudhoff H, Kaltschmidt B. Stem Cell-Induced Inflammation in Cholesteatoma is Inhibited by the TLR4 Antagonist LPS-RS. Cells 2020;9:E199. [PMID: 31947538 DOI: 10.3390/cells9010199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Duan ZJ, Zhang CL. Progress in developing rat models of hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2010; 18(30): 3204-3209 [DOI: 10.11569/wcjd.v18.i30.3204] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147-79. [DOI: 10.3390/livers1030014] [Reference Citation Analysis]
20 Kitazawa T, Tsujimoto T, Kawaratani H, Fukui H. Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats. J Gastroenterol Hepatol. 2010;25:1009-1012. [PMID: 20546456 DOI: 10.1111/j.1440-1746.2009.06145.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
21 Yang J, Nie QH, Wang AH, Huang XF, Liu QQ, Li YM. Effects of intestinal intervention on bacterial translocation in a rat model of acute liver failure in vivo. Eur J Gastroenterol Hepatol. 2010;22:1316-1322. [PMID: 20595903 DOI: 10.1097/MEG.0b013e32833ccaae] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Wang F, Zhou J, Chen E. Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis. Front Pharmacol 2022;13:787748. [DOI: 10.3389/fphar.2022.787748] [Reference Citation Analysis]
23 Ma H, Liu J, Du Y, Zhang S, Cao W, Jia Z, Gong W, Zhang A. Estrogen-Related Receptor γ Agonist DY131 Ameliorates Lipopolysaccharide-Induced Acute Liver Injury. Front Pharmacol 2021;12:626166. [PMID: 33967760 DOI: 10.3389/fphar.2021.626166] [Reference Citation Analysis]
24 Tsai TH, Tam K, Chen SF, Liou JY, Tsai YC, Lee YM, Huang TY, Shyue SK. Deletion of caveolin-1 attenuates LPS/GalN-induced acute liver injury in mice. J Cell Mol Med 2018;22:5573-82. [PMID: 30134043 DOI: 10.1111/jcmm.13831] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
25 Sankaranarayanan K, Antaris XX, Palanski BA, El Gamal A, Kao CM, Fitch WL, Fischer CR, Khosla C. Tunable Enzymatic Synthesis of the Immunomodulator Lipid IVA To Enable Structure-Activity Analysis. J Am Chem Soc 2019;141:9474-8. [PMID: 31184877 DOI: 10.1021/jacs.9b03066] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]